ADC Therapeutics AAQS 2025

Mit csinál ADC Therapeutics?

ADC Therapeutics SA is a biopharmaceutical company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of cancer. Founded in 2011, the company is headquartered in Lausanne, Switzerland. ADCs are customized drugs that consist of an antibody and a cytotoxic drug. The antibody is designed to specifically transport the cytotoxic drug to cancer cells and release it there to destroy the cancer cells. ADC Therapeutics uses a proprietary technology platform called Pyrrolobenzodiazepine (PBD) to manufacture ADCs that have high efficacy and improved safety. The company's business model involves developing and commercializing ADCs in various stages of research, clinical development, and market launch, in collaboration with partners from the pharmaceutical industry. ADC Therapeutics focuses on different types of cancer, including solid tumors such as breast cancer, lung cancer, prostate cancer, and colorectal cancer, as well as hematological tumors such as lymphomas and leukemias. The company has several ADC products in clinical development, including Camidanlumab tesirin (Cami) for the treatment of Hodgkin lymphomas and diffuse large B-cell lymphomas, and ADCT-601 for the treatment of solid tumors overexpressing the HORM2 receptor. ADC Therapeutics has also formed partnerships with other companies, such as Genmab, AstraZeneca, Adagene, and BioNTech, to further develop and commercialize its technology and products. The company aims to improve the quality of life for cancer patients worldwide by providing innovative drugs. ADC Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.